Simulations Plus

Accelerate drug development with AI-driven modelling, PBPK, and consulting. Trusted globally by pharma, biotech and regulatory organisations.
Find out more

Enquire about this software

Simulations Plus Overview

Simulations Plus delivers user-friendly modelling and simulation software alongside expert consulting services, supporting pharmaceutical companies, biotechnology firms and regulatory bodies worldwide. With over 25 years’ experience, Simulations Plus is recognised for advancing drug discovery, development, clinical research and regulatory submissions. Their proven solutions incorporate AI/ML, physiologically based pharmacokinetics (PBPK), quantitative systems pharmacology, and population PK/PD modelling, enabling more accurate predictions and informed decision-making throughout the R&D lifecycle.

The company offers industry-leading ADMET prediction, mechanistic pharmacokinetics modelling, and advanced disease modelling tools, supporting clients in accelerating research, reducing costs, and optimising treatment outcomes. Trusted by global pharma and biotech enterprises and regulatory agencies, Simulations Plus helps bridge AI and scientific modelling, driving results for both commercial and scientific stakeholders. Comprehensive resources, clinical operations support, and learning services further empower teams to successfully navigate complex drug development processes.

Features

GastroPlus Mechanistic Simulation

Enables accurate physiologically based pharmacokinetic (PBPK) modelling for drug absorption, distribution and metabolism, helping forecast outcomes and inform development strategies.

ADMET Predictor Machine Learning Platform

Delivers robust, AI-powered prediction of absorption, distribution, metabolism, excretion and toxicity (ADMET) properties, improving compound selection and reducing trial-and-error.

MonolixSuite for Pharmacometrics

Provides advanced statistical modelling, population PK/PD analysis and simulation, accelerating data-driven decision-making in clinical development and regulatory submissions.

DILIsym for Liver Injury Prediction

Specialised software for predicting drug-induced liver injury, supporting risk assessment and mitigation through mechanistic disease modelling and in silico simulation.

Key Benefits

  • User-friendly scientific software for modelling and simulation
  • Expert drug development consulting for accelerated R&D
  • Industry-leading ADMET property prediction
  • Mechanistic pharmacokinetics and PBPK modelling capabilities
  • AI-driven drug design and disease modelling tools
  • Optimises treatment options and outcomes
  • Comprehensive resource centre and learning services
  • Supports regulatory submissions and clinical operations
  • Reduces R&D costs while speeding development
  • Trusted by global pharmaceutical, biotechnology and regulatory organisations
QBS Brand Image
Adding Value QBS

Connect With Us

Speak to one of our vendor managers about your software requirements.

Contact Us
Enquire

Audience

  • Pharmaceutical researchers
  • Drug development teams
  • Clinical research professionals
  • Regulatory affairs specialists
  • Medical educators
  • Formulation scientists
  • Clinical operations professionals
  • Medical communications specialists
  • Pharmaceutical companies
  • Biotechnology firms
Miro cloud collaboration helps all teams - happy teams - Photo by Naassom Azevedo on Unsplash